Prognostic Role of Beta-2 Microglobulin in Diffuse Large B-Cell Lymphoma: Systematic Review and Meta-Analysis of Observational Studies
Abstract
Background: Evidence indicates that beta-2 microglobulin (β2M) plays a prognostic role in patients with diffuse large B-cell lymphoma (DLBCL).
Aim: However, due to controversies among previous studies, this meta-analysis was conducted to evaluate the prognostic role of β2M in DLBCL patients.
Methods and results: Relevant studies were identified through a systematic search using specific keywords in PubMed/Medline, Scopus, and Web of Science databases. Studies that provided complete information on the hazard ratio with a 95% confidence interval for β2M with respect to overall survival (OS) and progression-free survival (PFS) in multivariate models were included in the meta-analysis. A total of 30 studies, encompassing 25 128 patients, were included in this meta-analysis. The pooled analysis demonstrated a significant association between elevated β2M levels and poor OS in DLBCL patients (HR Pooled: 1.65, 95% CI: 1.45-1.88, p-value Pooled: 1.54, 95% CI: 1.39-1.70, p-value < 0.01).
Conclusion: The available evidence suggests that β2M serves as an independent prognostic marker with significant effects on OS and PFS in DLBCL patients. Elevated serum β2M levels are associated with poor prognosis and worse OS and PFS outcomes in DLBCL patients.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 25 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.